Diabetic Nephropathies Clinical Trial
Official title:
Evaluation of the Impact of a Comprehensive Clinical Management on the Quality of Blood Pressure and Glycemic Control in Diabetic Uremic Patients
Diabetes is the leading cause of end-stage renal disease in developed countries. Hypertension and metabolic control are known to affect the progression of renal deficiency and patient's outcome. Our project aims at implementing a multidisciplinary and systematic approach of diabetic patients with renal deficiency, and at evaluating the impact of metabolic and blood pressure targets as recommended by current guidelines.
Complications of diabetes are influenced by the quality of blood pressure control and of
metabolic control. Several prospective studies have shown a positive effect of the
implementation of such control, however metabolic and blood pressure targets are not
achieved for about 30% of diabetic uremic patients.
Our project aims at evaluating a comprehensive management approach of diabetic patients
affected by renal insufficiency, defined by glomerular filtration rate (GRF) <60 mL/min/1,73
m², through an alternate and complementary follow-up by the nephrologist and the
diabetologist.
During a first period (one year), patients are managed as “usually”. After this period, the
patients will start the multidisciplinary health care during at least two years. They will
be followed-up by the diabetologist every 4 months. According to his GFR measured by renal
clearance of Cr-EDTA, the patient will be followed-up by the nephrologist every year if the
GFR is between 60 and 40 ml/min, every 4 months if the GFR is between 40 and 20 ml/min, and
every 1 or 2 months if the GFR is under 20 ml/min. GFR will be re-evaluated every year
(Cr-EDTA or Cockcroft-Gault formula) and so medical examination frequency. Guidelines will
be applied regarding blood pressure control (objective: < 135/85 mmHg, and < 125/75 mmHg if
proteinuria > 1g/24H, choice of drugs, implementation of the treatment...) and glycemic
control (current guidelines according to the French Health Technology Information Agency,
ANAES). Another important component of the management will be the implementation of
nutritional balance and foot care.
Every two years, a detailed nutritional checkup will be planned by the diabetologist and a
cardiologic check-up will be planned by the nephrologist during one day in the local
nephrology department.
A biobank will be built up after patient's consent. We will assess the impact of this
intervention (guidelines application + multidisciplinary methodical and complementary
follow-up) in terms of glycemic and blood pressure control.
The percentage of patients who will obtain a good glycemic and blood pressure control will
be analysed and compared between the two follow-up period (before/after the intervention).
If validated this strategy may provide the basis of a care network focused on an optimum
diabetic health care.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Terminated |
NCT01575379 -
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
|
Phase 4 | |
Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
Not yet recruiting |
NCT04084886 -
TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
|
||
Active, not recruiting |
NCT04869761 -
Stem Cell Therapy for Chronic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT04570735 -
MRI Biomarkers in Diabetic Kidney Disease
|
||
Completed |
NCT03165240 -
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
|
Phase 1 | |
Completed |
NCT01968668 -
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
|
Phase 2 | |
Completed |
NCT02552277 -
A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Terminated |
NCT02410005 -
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
|
Phase 2/Phase 3 | |
Unknown status |
NCT01918488 -
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
|
N/A | |
Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT03165227 -
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
|
Phase 1 | |
Active, not recruiting |
NCT04531163 -
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
Completed |
NCT03334318 -
PERL Continuous Glucose Monitoring (CGM) Study
|
||
Not yet recruiting |
NCT03284996 -
Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.
|
N/A | |
Completed |
NCT04380584 -
Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
|